Pharmaceutical Executive-05-01-2013

Pharmaceutical Executive

Tracking Trial Cost Drivers: The Impact of Comparator Drugs and Co-Therapies

May 01, 2013

Features

0

0

New research from the Tufts Center for the Study of Drug Development identifies a significant contributor to the rising cost of clinical trials-the first step in meeting a growing strategic imperative to help senior management and the regulatory community craft new approaches to make trials more efficient in delivering results to clinicians and patients.

Country Report: Austria

May 01, 2013

Country Report

0

0

While Austria experienced significant political and economic shake-up throughout the 20th century, the country has remained a key strategic market for the pharmaceutical industry thanks to its steady economic development and inclination for innovation.

The Friendly Persuasion — An Interview with Fred Hassan

May 01, 2013

Features

0

0

What is industry icon Fred Hassan's management formula for staying fresh in an era of market churn?

The Patent Black Label

May 01, 2013

From the Editor

0

0

Last month's decision by India's Supreme Court to deny a patent for the top-selling oncologic drug Glivec took nearly a decade of litigation to resolve-but the implications in and beyond India are both immediate and lasting.

It's Time For a Code of Ethics in Patient Education

May 01, 2013

Column

0

0

In the world of patient education, processes, policies, and oversight differ vastly. There is no overarching governance structure. There isn't an accreditation process for educational interventions or patient advocacy organizations that develop the education.